安罗替尼靶向治疗伴PDGFR-α突变的H3K27M突变型弥漫性中线胶质瘤一例报告
Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
PubMed 文献 · Acta Neurochir (Wien) · 2021-11-23
本文报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者,伴PDGFR-α突变,接受多靶点酪氨酸激酶抑制剂安罗替尼治疗后获益,为这类患者提供了一种有前景的治疗选择。
要点
- H3K27M突变型弥漫性中线胶质瘤是2016年WHO中枢神经系统肿瘤分类第四版修订中定义的新实体。
- 安罗替尼是一种多靶点酪氨酸激酶抑制剂,此前未见用于H3K27M突变型弥漫性中线胶质瘤的报道。
- 本文首次报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者从安罗替尼治疗中获益。
核心结论
- 本文首次报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者从安罗替尼治疗中获益,为这类患者提供了一种有前景的治疗选择。
研究设计与样本
- 病例报告:一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者,伴PDGFR-α突变。
主要发现
- 该成人多灶性H3K27M突变型弥漫性中线胶质瘤患者接受安罗替尼治疗后获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
H3K27M-mutant diffuse midline glioma (H3K27M-mt DMG) was a novel entity, which was defined by K27M mutations in H3F3A or HIST1H3B/C in the 2016 WHO updated fourth edition of the central nervous system (CNS) tumor classification. There is an urgent need for effective therapeutic strategies. Anlotinib is a multitarget tyrosine kinase inhibitor, which has not been reported for H3K27M-mt DMG treatment. Here, we firstly reported an adult multifocal H3K27M-mt DMG patient benefiting from anlotinib. This report provides a promising treatment option for H3K27M-mt DMG patients.
来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。
引用
- Wang Q, Niu W, Pan H, et al. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report. Acta Neurochir (Wien). 2021. PMID: 34812950. doi:10.1007/s00701-021-05061-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。